Last reviewed · How we verify
cholecalciferol 6 lakh IU
Cholecalciferol 6 lakh IU, marketed by the Post Graduate Institute of Medical Education and Research, Chandigarh, holds a niche position in the vitamin D supplement market. The drug's key strength lies in its high-dose formulation, which may offer convenience and compliance benefits to patients. A primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | cholecalciferol 6 lakh IU |
|---|---|
| Also known as | vitamin D |
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease (PHASE4)
- Role of Calcium And Vitamin D In Nutritional Rickets And It's Management (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: